On July 7, Juno Therapeutics announced that the US Food and Drug Administration (FDA) had placed a clinical hold on the company’s phase 2 trial of its investigational immunotherapy, JCAR015, as a...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2aNtiAm
via
IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου